Business
Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia
SARASOTA, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced that it has received approval from the Human Research Ethics Committee (HREC) in Australia to initiate its Phase II clinical trial evaluating ONP-002, the Company's proprietary neuroprotective therapy, for the treatment of mild traumatic brain injury (mTBI), aka concussion. This approval marks
About this update from Oragenics Inc.
[{"type":"image","alt":"Oragenics","displaySize":"","headline":null,"caption":"Oragenics","className":"","disableSlideshowImg":false,"size":{"original":{"width":256,"height":256,"url":"https://media.zenfs.com/en/globenewswire.com/0212681d7f415be924a60d8016c09110"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ol2bqPWKKXmUHXexVg71mg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0212681d7f415be924a60d8016c09110","width":256,"height":256}},"lazy":false},{"type":"text","content":"SARASOTA, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced that it has received approval from the Human Research Ethics Committee (HREC) in Australia to initiate its Phase II clinical trial evaluating ONP-002, the Company's proprietary neuroprotective therapy, for the treatment of mild traumatic brain injury (mTBI), aka concussion.","length":484,"tagName":"p"},{"type":"text","content":"This approval marks a significant milestone in expanding Oragenics’ clinical development efforts internationally. With this clearance, Oragenics can initiate clinical trials in Australia and could begin patient enrollment as early as the second quarter of 2025. Once the Company is prepared to commence enrollment, patient enrollment and treatment administration is expected to occur in level 1 trauma emergency departments where concussed patients are often seen following motor vehicle accidents, falls, and contact sports","length":524,"tagName":"p"},{"type":"text","content":""Receiving HREC approval in Australia brings us one step closer to offering a much-needed therapeutic option for patients suffering from concussions," said Janet Huffman, Chief Executive Officer of Oragenics. "With enrollment sites considered in both Australia and New Zealand, we are significantly expanding the geographic footprint of our ONP-002 program as we move this critical drug trial forward.”","length":417,"tagName":"p"},{"type":"text","content":"ONP-002 is designed for intranasal administration, offering a non-invasive and efficient route for drug delivery to the brain. In preclinical models, ONP-002 has demonstrated the ability to reduce inflammation, oxidative stress, and brain swelling associated with con...